MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$1,444,044
Net cash provided by
(used in) operating...
$142
Net cash provided by
continuing financing...
$1,329,312
Net cash provided by
(used in)...
$142
Canceled cashflow
$114,732
Net (decrease) in
cash
-$324,411
Canceled cashflow
$1,329,454
(gain) loss on
derivative instruments
$74,366,000
Accounts payable
$1,371,226
Vesting expense
$371,335
Amortization of operating
lease right-of-use...
$141,982
Issuance of shares to
non-employees
$133,333
Depreciation and
amortization
$32,612
Inventories
-$4,717
Repayment of note payable
$76,674
Costs to issue common
stock and warrants
$38,058
Net cash (used in)
continuing operating...
-$1,653,865
Canceled cashflow
$76,421,205
Net loss from
continuing operations
-$77,646,737
Prepaid expense and
other assets
$273,341
Operating lease liability
-$141,739
Accrued expenses and
other
-$7,701
Accounts receivable
$3,052
Contract liabilities
-$2,500
Back
Back
Cash Flow
source: myfinsight.com
Predictive Oncology Inc. (POAI)
Predictive Oncology Inc. (POAI)